CASI Pharmaceuticals, Inc. CASIF
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -27.42% | 21.72% | 36.64% | 8.39% | -15.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.42% | 21.72% | 36.64% | 8.39% | -15.77% |
| Cost of Revenue | -38.84% | 71.02% | 86.55% | 52.75% | 25.78% |
| Gross Profit | -9.60% | -19.75% | -1.31% | -23.27% | -44.41% |
| SG&A Expenses | 12.47% | 8.09% | 18.08% | 10.16% | -0.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 100.00% | 99.96% | 99.96% | 99.89% | 99.97% |
| Total Operating Expenses | -6.19% | 31.14% | 40.60% | 27.46% | 14.52% |
| Operating Income | -9.26% | -37.70% | -43.77% | -47.74% | -55.11% |
| Income Before Tax | -22.39% | -60.41% | -74.62% | -34.76% | -49.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.39% | -60.42% | -74.62% | -35.13% | -49.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.39% | -59.57% | -72.49% | -32.90% | -45.74% |
| EBIT | -9.26% | -37.70% | -43.77% | -47.74% | -55.11% |
| EBITDA | -13.84% | -55.08% | -60.80% | -62.82% | -68.81% |
| EPS Basic | -7.50% | -33.83% | -40.81% | -10.01% | -25.17% |
| Normalized Basic EPS | 7.25% | -50.45% | -85.47% | -10.79% | -30.70% |
| EPS Diluted | -7.47% | -33.73% | -40.70% | -9.94% | -25.07% |
| Normalized Diluted EPS | 7.25% | -50.45% | -85.47% | -10.79% | -30.70% |
| Average Basic Shares Outstanding | 20.86% | 19.12% | 21.97% | 18.65% | 14.80% |
| Average Diluted Shares Outstanding | 20.86% | 19.12% | 21.97% | 18.65% | 14.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |